COVID-19 Treatment Guidelines Remove Sotrovimab Recommendation

April 08, 2022

The COVID-19 Treatment Guidelines Panel (the Panel) no longer recommends the anti-SARS-CoV-2 monoclonal antibody sotrovimab for the treatment of COVID-19 because the Omicron BA.2 subvariant is now the dominant subvariant circulating in the United States.

The Food and Drug Administration recently updated its Emergency Use Authorization for sotrovimab to state that the drug is no longer authorized for the treatment of COVID-19 in the United States. Although sotrovimab is active against the Omicron BA.1 and BA.1.1 subvariants, it has substantially decreased in vitro activity against the BA.2 subvariant.

The Panel has updated “Therapeutic Management of Nonhospitalized Adults With COVID-19” and removed the recommendations and rationale for the use of sotrovimab. The Panel has also updated the dosing information for tixagevimab plus cilgavimab (Evusheld) and added information about the paused distribution of sotrovimab.

For complete details on these updates, see What's New in the Guidelines on the COVID-19 Treatment Guidelines website.